Medical Condition News

RSS

Jumpstart and Portal Capital invest $500,000 in TheraVasc for PAD drug

JumpStart Inc., the Northeast Ohio venture development organization that accelerates the progress of high growth early-stage businesses, and Portal Capital, a Cleveland-based private equity firm investing in life science companies, each announce an investment commitment of $250,000 in TheraVasc Inc., for a total commitment of $500,000. The

6 Jan 2010

AMT receives Innovation Credit to develop gene therapy treatment for DMD

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that it will receive an Innovation Credit of up to EUR 4 million from the Dutch government to support the development of AMT's gene therapy treatment for Duchenne Muscular Dystrophy (DMD).

6 Jan 2010

ATP-sensitive potassium channel can contribute to fat deposition and obesity, new study says

A new study involving the University of Iowa, Mayo Clinic and two other institutions provides insight on weight control, suggesting that a ATP-sensitive potassium channel critical to survival and stress adaptation can contribute to fat deposition and obesity.

6 Jan 2010

Phase I clinical trial for Intellikine's INK128 inhibitor initiated

Intellikine, Inc. has initiated a Phase I clinical trial for its targeted anticancer drug INK128, a novel orally-available small molecule inhibitor of both the TORC1 and TORC2 complexes, key components of the PI3K/mTOR signaling pathway.

6 Jan 2010

Scott & White's CRI launches two clinical trials targeting cancers

Scott & White's Cancer Research Institute (CRI) has launched two clinical trials targeting cancers that affect both adults and children.

6 Jan 2010

Animal experiments show old antidepressant may reverse heart failure

A team of Johns Hopkins and other researchers have found in animal experiments that an antidepressant developed over 40 years ago can blunt and even reverse the muscle enlargement and weakened pumping function associated with heart failure.

6 Jan 2010

Excaliard Pharmaceuticals initiates Phase 2 trials of EXC 001

Excaliard Pharmaceuticals, Inc. announced today the initiation of three proof of concept Phase 2 trials of EXC 001, an antisense medicine that reduces fibrosis, for the amelioration of skin scarring and other fibrotic disorders.

6 Jan 2010

New research may yield more effective treatment for childhood leukemia

A team of Israeli scientists at the Sheba Medical Center's Research Center for Leukemia and Childhood Malignancies has discovered a method for developing a more effective and less perilous treatment for those suffering from childhood leukemia, the most common cancer in children.

6 Jan 2010

EnVivo Pharmaceuticals announces initiation and dosing of patients in Phase 2b study of EVP-6124

EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase 2b study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with schizophrenia. EnVivo is conducting the multi-center, dose ranging, placebo controlled, three-month study in the U.S. and Europe.

6 Jan 2010

Study indicates efficacy of antidepressants varies significantly depending on symptom severity

An analysis of randomized trials indicates that compared with placebo, the magnitude of benefit of antidepressant medications varies with the severity of depressive symptoms, and may provide little benefit for patients with mild or moderate depression, but appear to provide substantial benefit for patients with very severe depression, according to an article in the January 6 issue of JAMA.

6 Jan 2010

Lerner Medical Devices' Levia receives FDA clearance

Lerner Medical Devices, Inc. announced today that Levia®, a novel, in-home, ultraviolet B (UVB) phototherapy device, has received 510 (k) clearance from the U.S. Food and Drug Administration (FDA) for treatment of psoriasis and certain other skin conditions such as vitiligo.

6 Jan 2010

Health Canada approves Zyclara Cream for multiple actinic keratoses

Health Canada has approved Zyclara™ (imiquimod) Cream 3.75%, a topical prescription treatment for multiple actinic keratoses (AK) located on the face or balding scalp in adults. Actinic Keratosis is a common skin condition that can lead to squamous cell carcinoma, a form of non-melanoma skin cancer, if left untreated.

6 Jan 2010

States that receive federal funds are more likely to implement obesity-prevention programs

States that received funding from two obesity prevention programs founded by the U.S. Centers for Disease Control & Prevention implemented more than twice as many obesity-prevention policy initiatives as states that did not receive funding, according to a study by researchers from RTI International.

6 Jan 2010

Excessive reduction of fat mass in girls may increase risk of osteoporosis in later life

According to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM), fat mass is important in increasing bone size and thickness, but this effect appears to be stronger in girls than boys.

6 Jan 2010

Preclinical data of Geron's telomerase inhibitor drug published

Geron Corporation today announced the publication of preclinical data demonstrating that its telomerase inhibitor drug, imetelstat (GRN163L), inhibited telomerase activity and reduced tumor size in xenograft models of glioblastoma, and inhibited the activity of glioblastoma stem cells in culture.

6 Jan 2010

Multidisciplinary care, patient decision aids rarely offered by breast cancer surgeons

Most breast cancer surgeons' practices do not follow standards associated with the best quality of care, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.

6 Jan 2010

Cancer Research UK and CRT to undertake phase I clinical trial of DI-B4

CANCER RESEARCH UK and Cancer Research Technology (CRT), the charity's development and commercialisation arm, are to undertake a phase I clinical trial of an investigational monoclonal antibody1 drug from Merck KGaA, Darmstadt, Germany, called DI-B4 - it is announced today (Monday).

6 Jan 2010

IME introduces new drug-free pain relief alternative for headache

Innovative Medical Equipment, LLC. (IME) today announced the full U.S. market release of SOOTHEAWAY - a new, thermo-electrically heated and cooled therapy device that helps relieve migraine, tension or stress headache pain in the forehead, temples, occipital and ocular / sinus regions.

6 Jan 2010

Enrollment in Boston Scientific's MAPS clinical trial completed

Boston Scientific Corporation today announced that it has completed enrollment in its MAPS(TM) clinical trial, which is studying the coiling of intracranial aneurysms.

6 Jan 2010

Study reveals hereditary factors contribute to abdominal aortic aneurysm in twins

A new study in the January issue of the Journal of Vascular Surgery(®), published by the Society for Vascular Surgery®, reveals robust epidemiological evidence that hereditary factors contribute to aneurysm formation in twins.

6 Jan 2010